<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03299946</url>
  </required_header>
  <id_info>
    <org_study_id>J17136</org_study_id>
    <secondary_id>IRB00149350</secondary_id>
    <nct_id>NCT03299946</nct_id>
  </id_info>
  <brief_title>Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is an open-label, single institution, single arm phase 1b study of
      neoadjuvant cabozantinib plus nivolumab in patients with locally advanced HCC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events in participants of neoadjuvant cabozantinib plus nivolumab.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients who complete pre-op treatment and proceed to surgery.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who obtain R0 resection.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who obtain a pathologic complete response (CR).</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who obtain a major pathologic responses (MPR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Locally Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>XL184</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>OPDIVO, BMS 936558, MDX-1106, ONO-4538</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have locally advanced/borderline resectable hepatocellular carcinoma.

          2. Must have measurable disease.

          3. Age â‰¥18 years.

          4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          5. Patients must have adequate organ and marrow function defined by study-specified
             laboratory tests.

          6. Patients must have adequate liver remnant and function.

          7. Antiviral therapy per local standard of care for hepatitis B.

          8. Woman of child bearing potential must have a negative pregnancy test.

          9. Must use acceptable form of birth control while on study.

         10. Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Fibrolamellar carcinoma or mixed HCC.

          2. Chemotherapy, radiotherapy, investigational therapy, or surgery less than 6 months
             prior to trial registration.

          3. Concomitant Anticoagulation therapy.

          4. Any GI or pulmonary risks of bleeding.

          5. History of HIV Infection.

          6. Active co-infection with hepatitis B and hepatitis C.

          7. Active co-infection with hepatitis B and hepatitis D.

          8. Has a diagnosis of immunodeficiency, or is receiving systemic steroid therapy.

          9. History of any autoimmune disease requiring systemic treatment within the past 2
             years. Any patient bearing an allograft is not eligible.

         10. Any additional malignancies with treatment or life-limiting cancers. Superficial
             bladder cancer, non-melanoma skin cancers, or low grade prostate cancer not requiring
             therapy would not exclude participation in this trial.

         11. Uncontrolled intercurrent illness.

         12. Corrected QT interval calculated by the Fridericia formula.

         13. Uncontrolled high blood pressure.

         14. Are pregnant or breastfeeding.

         15. Any gastrointestinal (GI) disorders.

         16. Any certain study-specified heart conditions 6 months prior to enrollment.

         17. Major surgery within 2 months before enrollment.

         18. Have any evidence of moderate or severe ascites.

         19. Any untreated or incompletely treated varices with bleeding or high-risk bleeding.

         20. Inability to swallow intact tablets.

         21. Known or suspected hypersensitivity to study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Laheru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Yarchoan, MD</last_name>
    <phone>410-955-8893</phone>
    <email>mark.yarchoan@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sartorius-Mergenthaler, MA, RN</last_name>
      <phone>410-614-3644</phone>
      <email>Sartosu@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tearra Miles</last_name>
      <phone>410-502-5328</phone>
      <email>tlawre18@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Laheru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Yarchoan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2017</study_first_submitted>
  <study_first_submitted_qc>September 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Cabozantinib</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>Borderline Resectable</keyword>
  <keyword>Advance Resectable</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>Resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

